Haploidentical and Matched Sibling Transplantation for Acute Myeloid Leukemia: A Hospital-Based Study.
Juan C BaenaMaria C RosalesMayra EstacioAlejandra HidalgoElizabeth ArrietaFrancisco J JaramilloEliana ManziLuis Gabriel Parra-LaraJoaquin D RosalesPublished in: Journal of hematology (2023)
These results underline that MSD remains the first donor choice for AML patients in CR1 when available. HRDs are still our next option among alternative donors. It is necessary to find strategies that have a positive impact on those outcomes that markedly affect the quality of allogeneic PBSCT and the prognosis of patients. Comparative, randomized, prospective studies with longer follow-up of haploidentical allogeneic PBSCT with other donor types are required to definitely establish its role among alternative donors.
Keyphrases
- stem cell transplantation
- acute myeloid leukemia
- bone marrow
- end stage renal disease
- ejection fraction
- newly diagnosed
- prognostic factors
- randomized controlled trial
- type diabetes
- clinical trial
- low dose
- peripheral blood
- double blind
- kidney transplantation
- weight loss
- decision making
- patient reported
- placebo controlled